Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus

PHASE4UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Chronic Kidney DiseasesHeart Transplant
Interventions
DRUG

Conversion from IR Tacrolimus to XR Tacrolimus

All participants will be consented to the study on IR Tacrolimus. After their baseline visit, they will be converted to XR Tacrolimus

Trial Locations (1)

60153

RECRUITING

Loyola University Medical Center, Maywood

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Veloxis Pharmaceuticals

INDUSTRY

lead

Loyola University

OTHER